[1]赵 猛,孙 娟,褚 璇.苯扎贝特改善2型糖尿病合并高甘油三酯血症患者 胰岛素抵抗的临床分析[J].医学信息,2019,(17):145-147.[doi:10.3969/j.issn.1006-1959.2019.17.048]
 ZHAO Meng,SUN Juan,CHU Xuan.Clinical Analysis of Bezafibrate in Improving Insulin Resistance in Patients with Type 2 Diabetes Mellitus Complicated with Hypertriglyceridemia[J].Medical Information,2019,(17):145-147.[doi:10.3969/j.issn.1006-1959.2019.17.048]
点击复制

苯扎贝特改善2型糖尿病合并高甘油三酯血症患者 胰岛素抵抗的临床分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年17期
页码:
145-147
栏目:
药物与临床
出版日期:
2019-09-01

文章信息/Info

Title:
Clinical Analysis of Bezafibrate in Improving Insulin Resistance in Patients with Type 2 Diabetes Mellitus Complicated with Hypertriglyceridemia
文章编号:
1006-1959(2019)17-0145-03
作者:
赵 猛孙 娟褚 璇
徐州医科大学附属医院内分泌科,江苏 徐州 221002
Author(s):
ZHAO MengSUN JuanCHU Xuan
Department of Endocrinology,Affiliated Hospital of Xuzhou Medical College,Xuzhou 221002,Jiangsu,China
关键词:
2型糖尿病高甘油三酯血症苯扎贝特非诺贝特胰岛素抵抗
Keywords:
Key words:Type 2 diabetesHypertriglyceridemiaBezafibrateFenofibrateInsulin resistance
分类号:
R544.1;R589.2
DOI:
10.3969/j.issn.1006-1959.2019.17.048
文献标志码:
A
摘要:
目的 探讨苯扎贝特对2型糖尿病合并高甘油三酯血症患者降低血脂,同时改善胰岛素敏感性的影响及作用机制。方法选取我院2016年12月~2018年2月收治的符合入选标准2型糖尿病合并高甘油三酯血症患者56例,随机分为A组(n=29)和B组(n=27)。两组均使用苯扎贝特及非诺贝特降脂治疗,其他常规服用药物不变。A组:治疗顺序为苯扎贝特+非诺贝特,疗程各1个月,期间清洗期为1周;B组:治疗顺序为非诺贝特+苯扎贝特,疗程各1个月,期间清洗期为1周。监测两组患者实验前、第一阶段及第二阶段的甘油三酯(TG)、胆固醇、空腹血糖(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS),并计算胰岛素敏感指数(IsI)。结果 两组患者实验前、第一阶段和第二阶段的TG和胆固醇水平比较,差异无统计学意义(P>0.05)。两组实验前和第一阶段的FBG、HbA1c及IsI比较,差异无统计学意义(P>0.05);B组第二阶段的FBG高于A组[(6.73±0.28)mmol/L vs (6.52±0.51)mmol/L],HbA1c和IsI均低于A组[(6.54±0.32)% vs (6.76±0.71)%,(-4.19±0.34)vs(-4.13±0.28)],差异有统计学意义(P<0.05)。结论 苯扎贝特可改善血脂,调节糖代谢,降低2型糖尿病患者血糖,并能改善胰岛β细胞分泌功能,提高机体胰岛素敏感性。
Abstract:
Abstract:Objective To investigate the effect and mechanism of bezafibrate on reducing blood lipids and improving insulin sensitivity in patients with type 2 diabetes mellitus complicated with hypertriglyceridemia.Methods A total of 56 patients with type 2 diabetes mellitus complicated with hypertriglyceridemia who were admitted to our hospital from December 2015 to February 2018 were randomly divided into group A (n=29) and group B (n=27).Both groups were treated with bezafibrate and fenofibrate lipid-lowering drugs, and other conventional drugs were unchanged. Group A: The order of treatment was bezafibrate + fenofibrate, the time course was 1 month, and the cleaning period was 1 week; Group B: the treatment order was fenofibrate + bezafibrate, and the time course was 1 month.The period of cleaning is 1 week. Triglyceride (TG), cholesterol, fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), and insulin sensitivity index (IsI) were calculated before, during the first and second phases of the two groups.Results There were no significant differences in TG and cholesterol levels between the two groups before, during the first and second phases (P>0.05). There was no significant difference in FBG, HbA1c and IsI between the two groups before and after the experiment (P>0.05). The FBG in the second stage of group B was higher than that in group A [(6.73±0.28) mmol/L vs (6.52±0.51)mmol/L], HbA1c and IsI were lower than group A [(6.54±0.32)% vs (6.76±0.71)%, (-4.19±0.34) vs (-4.13±0.28)], the difference was statistically significant (P<0.05).Conclusion Bezafibrate can improve blood lipids, regulate glucose metabolism, reduce blood sugar in patients with type 2 diabetes, improve the secretion function of islet β cells, and improve insulin sensitivity.

参考文献/References:

[1]Nelson AJ,Rochelau SK,Nicholls SJ.Managing Dyslipidemia in Type 2 Diabetes[J].Endocrinol Metab Clin Norrth Am,2018,47(1):153-173. [2]Baez-Duarte BG,Zamora-Gínez I,González-Duarte R,et al.Triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) index as a reference criterion of risk for metabolic syndrome(MetS) and low insulin sensitivity in apparetly healthy subjects[J].Gac Med Mex,2017,153(2):152-158. [3]Petrie JR,Guzik TJ,Touyz RM.Diabetes,Hypertension,and Cardiovascular Disease:Clinical Insights and Vascular Mechanisms[J].Can J Cardiol,2018,34(5):575-584. [4]Stinchcombe TE,Socinki MA.Treatment paradigms for advanced stage nonsmall cell lung cancer in the era of multiple lines of therapy[J].J Thoracic Oncol,2009,4(2):243-250. [5]Kent BD,Mcnicholas WT,Ryan S.Insuiin resistance,glucose intolerance and diabetes mellitus in obstructive sleep apnoea[J].J Thorac Dis,2015,7(8):1343-1357. [6]Hardie DG.Keeping the home fires burning:AMP-activated protein kinase[J].J R Soc Interface,2018,15(138):20170774. [7]Greco C,Spallone V.Obstructive sleep Apnoea syndrome and Diabetes.Fortuitous Association or Interaction?[J].Curr Diabetes Rev,2015,12(2):129-155. [8]Ceccato F,Bernkopf E,Scaroni C.Sleep apnea syndrome in endocrine clinics[J].Journal of Endocrinological Investigation,2015,38(8):827-834. [9]Wu L,Parhofer KG.Diabetic dysljpidemia[J].MetaboIism,2014,63(12):1469-1479. [10]Wang T,Xu Y,Xu M,et al.Awareness,treatment and control of cardiometabolic disorders in Chinese adults with diabetes:anational representative population study[J].Cardiovasc Diabetol,2015(14):28. [11]李菁爽,张立海,王跃生,等.罗格列酮对初发2型糖尿病患者血糖、炎症因子和胰岛素抵抗的影响机制研究[J].中国医药导报,2013,10(8):19-21. [12]刘小翠,潘海林.二甲双胍联合罗格列酮治疗肥胖2型糖尿病患者糖脂代谢及胰岛素抵抗的影响[J].广西医科大学学报,2010,27(3):434-436. [13]曲颖,张纯利,胡文娟,等.西格列汀、罗格列酮分别联合二甲双胍治疗老年2型糖尿病的疗效观察[J].现代生物医学进展,2013,12(21):4077-4080.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
 HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,(17):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
 DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,(17):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,(17):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,(17):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
 LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,(17):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
 LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,(17):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
 DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,(17):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
 LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2018,(17):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
 BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Medical Information,2018,(17):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 2019-09-01